Welcome to Johns Hopkins Health Alerts!

"Johns Hopkins Health Alerts is an excellent site and I have recommended it to several of my friends. Thanks again, and keep up the good work!"
  • - D. Ambrosio


This free public service from Johns Hopkins Medicine helps keep you up to date on the latest breakthroughs for the most common medical conditions which prevent healthy aging.

Get the latest news sent straight to your inbox for FREE. Check all the boxes below for the topics that interest you.
We value your privacy and will never rent your email address

Johns Hopkins Health Alert

Pristiq: A New SNRI for Depression

Comments (1)

Dr. Karen L. Swartz, Director of the Johns Hopkins Mood Disorders Center, answers a reader’s question about the therapeutic benefits of Pristiq, a new antidepressant: I am currently on Effexor (venlafaxine), which has a similar generic name, so I'm wondering how Pristiq differs from Effexor and other SNRIs? Chester, VT

Dr. Swartz: Pristiq (desvenlafaxine succinate) is an antidepressant in the serotonin and norepinephrine reuptake inhibtor (SNRI) class of drugs. Pristiq is indeed very closely related to Effexor (venlafaxine hydrochloride) chemically. In fact, it is metabolic byproduct of Effexor. Pristiq, like Effexor XR, is dosed once daily.

 

What is reported to be different about Pristiq is that the antidepressant medication can be started at a dose high enough to potentially be therapeutic. One of the great challenges with antidepressants is that, for almost all of them, they need to be started at low doses and slowly increased to a potentially therapeutic dose. Since it is impossible to predict which antidepressant will be effective for a given person, the time spent adjusting the dose can be very frustrating, especially if the antidepressant dose not eventually help.

 

For Pristiq, it is recommended to start with a dose of 50 mg daily, which is also typical maintenance dosage. This guideline is based on two things: data showing inconsistent improvement with dosage increments and the finding that patients are generally able to tolerate 50 mg daily as a starting dose.

Pristiq has been shown to be safe at higher doses, but a decision to increase dosage should be made in collaboration with the your psychiatrist and/or primary care physician.

Pristiq, Effexor, and other SNRI's such as Cymbalta have not proven markedly different in their effectiveness. (For that matter, there is not strong evidence that any particular antidepressant or class of antidepressants is superior to another for everyone.) For this reason, if someone is doing well on Effexor, it would be wise to consider staying on that medication rather than switching to another SNRI, including Pristiq.

Posted in Depression and Anxiety on August 19, 2009
Reviewed January 2011


Medical Disclaimer: This information is not intended to substitute for the advice of a physician. Click here for additional information: Johns Hopkins Health Alerts Disclaimer


Notify Me

Would you like us to inform you when we post new Depression and Anxiety Health Alerts?

Post a Comment

Comments

Health Alerts registered users may post comments and share experiences here at their own discretion. We regret that questions on individual health concerns to the Johns Hopkins editors cannot be answered in this space.

The views expressed here do not constitute medical advice, and do not represent the position of Johns Hopkins Medicine or Remedy Health Media, LLC, which has no responsibility for any comments posted on this site.


I have been taking Pristiq to manage hot flashes which has been fairly effective. I also have dysthymia so it serves both purposes. What I want to know is, what others have experienced in relation to weight gain/loss. I have not gained weight but have been trying to lose weight since April and have been unable. I have also been on Wellbutrin for the last 10 years but have stopped that in the last month and am wondering if that could be the reason I am not losing weight.

Posted by: markegard | August 22, 2009 5:00 PM

Post a Comment


Already a subscriber?

Login

Forgot your password?

New to Johns Hopkins Health Alerts?

Register to submit your comments.

(example: yourname@domain.com)

Customer Service

Registered Users Log-in:

Forgot Password?

Become a Registered User!
It's fast and FREE!
The Benefits of Being a Registered User

Johns Hopkins Depression White Papers

2014 Depression and Anxiety White Paper

How To Cope More Effectively With Depression

With new medications that promise greater relief with fewer side effects, as well as dramatic breakthroughs in diagnosis and treatment, Johns Hopkins specialists are expertly prepared to help you find relief. The very latest information and their best professional advice are spelled out in an important new Johns Hopkins White Paper for informed health consumers like you.

Read More or Order.




Managing Bipolar Disorder

If you or a loved one has bipolar disorder, you know first-hand what it’s like to live with the ups and downs of this serious mood disorder. The good news is that when properly diagnosed it can be managed effectively with medications and other therapies. That’s why Karen Swartz, M.D and a team of world-famous psychiatrists at Johns Hopkins have gathered together to write Managing Bipolar Disorder. Managing Bipolar Disorder provides the latest thinking on the causes of bipolar disorder and the full range of your treatment options -- including medications and electroconvulsive therapy. This authoritative 70-page special report contains current information you won’t find in any other single source. Read more or order Managing Bipolar Disorder Digital Report




Health Topic Pages

  • Health Alert
  • Special Report

What is this?

XML